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Background: Strokes are commonly preceded by transient ischemic attacks (TIAs). TIA is often associated with
metabolic syndrome (causing chronic inflammation), resulting in a proinflammatory- and procoagulant-
environment. The aim of this study was to determine whether platelet- and fibrin network-morphology or
coagulation profiles of individuals that suffered a TIA in the presence of metabolic syndrome was altered when
compared to healthy individuals.
Materials and methods: The study consisted of 40 voluntary participants. Twenty individuals that suffered a TIA in
the previous 48 h with at least two metabolic syndrome risk factors present and twenty healthy age-matched
controls. Scanning electron- and atomic force microscopy was used to study platelet- and fibrin-morphology,
atomic force microscopy was used to study platelet- and fibrin fiber-elasticity and thromboelastography® for the
study of coagulation profiles. Statistical analysis was performed to compare the two groups. In all cases a p-value of
less than 0.05 was considered statistically significant.
Results: Platelets of the control group appeared spherical with few pseudopodia present while the platelets of the
TIA individuals presented with numerous pseudopodia and spreading, indicating activation. Platelet aggregation
was also present. The fibrin networks of the healthy individuals consist of thick and thin fibers that form an
organized network of fibers. The fibrin networks of the TIA individuals appeared less organized with less taut fibers.
Fibrin fiber thickness was found to be significantly increased in the TIA group (p-value <0.001) when compared to
healthy controls. The thicker fibers formed irregular networks with thick masses of fibrin fibers. Platelet and fibrin
fiber elasticity was found to be significantly lower in the experimental group (p-value 0.0042 and p-value 0.0007
respectively). The hemostatic profiles of the diseased individuals did not differ significantly (p-value > 0.05) from the
healthy controls, indicating a normal functioning coagulation cascade.
Conclusion: The findings indicate that pathological clot formation is not caused by alterations in the coagulation
cascade but rather by the premature activation of platelets (as a result of chronic inflammation) that in turn causes
altered fibrin formation.
Keywords: Transient ischemic attack, Coagulation, Platelets, Fibrin network, Metabolic syndrome, Chronic
inflammation, Electron microscopy, Thromboelastography®* Correspondence: resia.pretorius@up.ac.za
1Department of Physiology, Faculty of Health Sciences, University of Pretoria,
Private Bag x323, Arcadia 0007, South Africa
Full list of author information is available at the end of the article
© 2015 van Rooy et al. Open Access This ar
4.0 International License (http://creativecom
and reproduction in any medium, provided
provide a link to the Creative Commons lic
Domain Dedication waiver (http://creativec
this article, unless otherwise stated.ticle is distributed under the terms of the Creative Commons Attribution
mons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
you give appropriate credit to the original author(s) and the source,
ense, and indicate if changes were made. The Creative Commons Public
ommons.org/publicdomain/zero/1.0/) applies to the data made available in
van Rooy et al. Cardiovascular Diabetology  (2015) 14:86 Page 2 of 13Background
Ischemic heart disease and stroke accounts for 25 % of
deaths in the world every year and in the USA 240 000
people suffer a transient ischemic attack (TIA) annually
[1, 2]. TIA is defined as: “A brief episode of neurologic
dysfunction caused by focal brain or retinal ischemia,
with clinical symptoms typically lasting less than one
hour and without evidence of acute infarction” [3, 4].
TIAs, similar to angina, is usually an ominous predictor
of future vascular complications [5]. The likelihood of
suffering a stroke after a TIA is higher than suffering a
recurrent stroke after a first stroke, indicating that TIAs
should be treated with the utmost care in order to avoid
possible events that may have severe neurological conse-
quences [5]. Although several physical characteristics
(such as age) can increase the likelihood of an ischemic
event occurring [1], metabolic syndrome is currently the
most prominent risk factor associated with these events
[6]. For this manuscript the National Cholesterol Educa-
tion Program – Adult Treatment Panel III (NCEP ATP
III) definition was employed since this definition links
the pro-thrombotic- and proinflammatory-state seen
with metabolic syndrome and thrombotic events. Fur-
thermore since no definite conclusion has been reached
regarding criteria that should be absolutely required, this
definition circumvents this controversy by suggesting
that all risk factors play a role in the development of
metabolic syndrome and its complications [7].
Metabolic syndrome is linked to chronic inflammation -
another major risk factor for the development of ischemic
events, since inflammation is linked to alterations in co-
agulation [6, 8]. For a review on blood coagulation in nor-
mal physiology and specifically platelet action see one of
the following [6, 9–11]. Important to mention for this
study is that fibrin and platelets are the major role players
in both the elasticity and rigidity of the formed clot [12].
The elastic properties of fibrin and platelets allow clot de-
formation to occur under normal physiological conditions,
but also influence the rigidity of the clot. Since fibrin fibers
are stiffer when stretching than when bending, the
elasticity of the clot is dependent on the cross-linking
of the fibers as well as the interaction between the fi-
bers and platelets [13, 14]. Once fibrin fibers and plate-
lets have formed the initial clot, platelet contraction
occurs that decreases the size of the clot (retraction)
and also places strain on the fibrin fibers, thereby al-
tering fibrin fiber rigidity as well as organisation of the
fibers [12].
In the presence of inflammation, normal physiological
coagulation is altered when the inflammatory mediators
modify the endothelium in the damaged area to become
proinflammatory and pro-thrombotic [9]. Importantly in-
flammation is further associated with thrombosis since co-
agulation is stimulated by inflammation and inflammationis enhanced in the presence of procoagulant activity
[15–17]. Inflammation influences coagulation by in-
creasing the production of coagulation proteins, redu-
cing the activity of the anticoagulant pathway and by
preventing fibrinolysis [17, 18]. Together these alter-
ations could lead to the formation of pathological
thrombi resulting in infarcts in the heart or brain. Al-
though atherosclerosis may be one cause of TIA, the
presence of metabolic syndrome could affect the coagu-
lation system in some way, leading to a TIA even before
atherosclerosis develops.
Since a large number of individuals that are affected
by metabolic syndrome suffer cerebral ischemic events,
finding new therapeutic targets by elucidating new fac-
tors that contribute to these incidents are crucial to the
treatment and prevention of the events. This manuscript
consequently focuses on the alterations of the coagula-
tion system in TIA individuals in the presence of the
metabolic syndrome. Special attention was paid to plate-
lets and fibrin networks and the effect on the overall
hemostatic profile of the participants using scanning
electron- (SEM) and atomic force-microcopy (AFM) as
well as thromboelastography® (TEG®).
Materials and methods
Sample selection
Twenty voluntary participants (between the ages of 39
and 78) that suffered a TIA in the presence of the risk
factors associated with metabolic syndrome using the
NCEP ATP III criteria were included in this study as ex-
perimental group, along with 20 healthy, age-matched
individuals that served as the control group. The Human
Ethics Committee of the University of Pretoria granted
ethical clearance for this study. A qualified neurologist
made the diagnosis of TIA after several diagnostic (e.g.
magnetic resonance imaging) and laboratory-based
blood tests (e.g. platelet count and coagulation parame-
ters) were performed. Blood samples, via venipuncture,
for this study were collected after informed consent
was obtained from all participants. Blood was drawn
from patients within 48 h after the TIA attack to ensure
that the acute phase of the attack was studied. Several
inclusion and exclusion criteria were used to determine
eligibility for this study.
Experimental group
Inclusion criteria:
 A definite diagnosis of TIA (any uncertainty
regarding diagnosis resulted in ineligibility for
participation in the study)
 Males and females over the age of 18 years
 At least two metabolic syndrome symptoms present
when the TIA occurred
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 Smoking
 Heavy drinking as indicated in patient history that
could confound inflammatory effects
 Hormone replacement therapy
 Known common inflammatory conditions such as
asthma, human immunodeficiency virus (HIV) or
tuberculosis not related to the risk factors associated
with metabolic syndrome
 Treatment with tissue plasminogen activator directly
after the event to prevent any confounding of results
regarding the coagulation profile
Since metabolic syndrome is a pre-diabetic condition,
diabetes was not excluded in this study.
Of the 20 experimental participants all 20 were viscer-
ally obese, 17 had diagnosed hypertension, 18 hyperchol-
esterolemia and 12 a high fasting glucose. No carotid
stenosis was detected in any of the participants with
magnetic resonance angiography or with echocardiog-
raphy of the carotid arteries. Two individuals had sub-
clinical calcified plaque present in the carotid arteries, 2
had an increased intima media thickness unilaterally and
2 bilaterally. Only 1 patient was diagnosed with athero-
sclerosis. Two individuals had valve disease, most likely
as a result of hypertension, 1 had left ventricular hyper-
trophy and 3 patients tachycardia. Although tachycardia
had been diagnosed at the time of the attack the electro-
cardiogram (ECG) of 1 patient indicated tachycardia, the
other 2 had normal ECG recordings due to effective
treatment. A careful inventory of chronic medication or
treatments after the attack was taken to determine
whether the medication could affect the results of this
study. The medications with known effects on coagula-
tion are summarized in Table 1. Since all the patientsTable 1 Medication and the effect on coagulation
Medication Nr of patients Medication administered
Anticoagulant 4 Warfarin, Xarelto, Clexan
Cox-1 inhibitor 12 Ecotrin, Disprin CV, Disp
P2Y12-inhibitor 5 Plavix (Clopidogrel)
β-blocker 6 Adco-biscor, Bilocor, Ten
Bisoprolol, Hypotone, Ca
Decreased fasting glucose agent 4 Arrow metformin, Gluco
Galvus, Starlix
Synthetic insulin 1 Levemir
GABA derivatives 2 Nootropil
Nr Number, Ref Reference, Cox-1 cyclo-oxygenase 1, β-blocker Beta blocker, TXA2 Thwere either on anticoagulants prior to the attack or
treated with anticoagulants and/or antiplatelet medica-
tion after the attack, these drugs could decrease the co-
agulation potential of the individual. Since the findings
of this study could be blunted by the presence of the
drugs, the significant findings of the study regardless of
the presence of anticoagulants or antiplatelet therapy
makes these findings even more important. For this
reason the use of anticoagulants or antiplatelet medica-
tion was not used as an exclusion criterion in this
study.Healthy group
Inclusion criteria:
 Over the age of 18 years




 Chronic diseases or medication use
 Hormone replacement therapy or other medication
that could affect coagulation
 Any risk factors associated with metabolic syndromeScanning electron microscopy
SEM was used to study platelet- and fibrin fiber-
morphology as well as to determine fibrin fiber thickness
in both groups. Platelet- and fibrin network-morphology
were studied by preparing platelet-rich plasma (PRP).
PRP was prepared by drawing 5 ml of blood in a sodium
citrate vacuum tube (3,8 % final concentration: BD
Vacutainer). The blood sample was centrifuged atComment Ref
e Decrease production of coagulation factors by the liver. [41]
rin Inhibits cox-1 activity thereby preventing the production
of TXA2 and platelet aggregation
[42]
Prevents release of ADP and thereby the activation of




Down regulates TXA2 production, but not platelet
aggregation and therefore not significant effect
on coagulation
[43]
phage, Decreases the amount of PAI-1 available, thereby
influencing fibrinolysis
[44]
Hyperinsulinaemia may decrease fibrinolysis, so
treatment can normalise fibrinolytic activity
[45]
Appears to have an antithrombotic effect,
but mechanism not elucidated as yet
[46]
romboxane A2, GABA Gamma-aminobutyric acid
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10 mm glass coverslips.
Ten μl of PRP was used to study platelet morphology
and 10 μl of PRP was mixed with 5 μl of human throm-
bin to study fibrin network morphology. Since red
blood cells that are incorporated into clots have been
found to alter the thickness of fibrin fibers, PRP was
used to study fibrin thickness. The South African
National Blood Service (SANBS) supplied human
thrombin. The thrombin solution was at a concentra-
tion of 20 U/ml and was made up in a biological buffer
containing 0.2 % human serum albumin. When throm-
bin is added to the freshly prepared human PRP or
whole blood, the fibrinogen is converted to fibrin and
other intracellular platelet components are released
into the coagulum. These components include, but are
not limited to transforming growth factor, platelet-
derived growth factor and fibroblastic growth factor.
The glass coverslips were incubated at 37 °C for
10 min. After incubation the cover slips were placed in
phosphate buffer (PB) solution on a shaker and washed
for 20 min. The wash step was included to remove any
blood proteins that may be entangled in the formed
blood clot. The samples were then fixed for 30 min in a
mixture of 2,5 % gluteraldehyde and 2,5 % formalde-
hyde solution. After the fixation step the samples were
washed three times in PB solution for 3 min to remove
any residual fixative. The samples were then fixated a
second time in 1 % osmium tetroxide (OsO4) for
15 min. This step was followed by another washing
step, which included three washes for 3 min in PBS.
The samples were then serially dehydrated in 30 %,
50 %, 70 %, 90 % and finally three times in 100 % etha-
nol. The samples were dried using hexamethyldisila-
zane (HMDS), and mounted and coated with carbon.
Once the samples were coated they were examined
using a SEM (Zeiss ULTRA plus FEG SEM).
It has been established that fibrin networks, and
therefore blood clots consist of thick and thin fibrin fi-
bers [19, 20]. In order to determine whether changes in
fibrin fiber thickness were present when comparing
healthy and metabolic syndrome TIA individuals, 50
random fibrin fibers were measured for each partici-




AFM was used to study the elastic properties of the
platelets and fibrin fibers of the two groups. The prepar-
ation of platelets and fibrin networks for AFM is identi-
cal to that of SEM, except after drying the samples with
HMDS; the samples were not coated with carbon. The
samples were left to air dry before being analyzed.AFM measurements and imaging
Topographic images were obtained to compare the
morphology of the cells and fibers studied for AFM to
that of the SEM. The images were obtained by using
an AFM (Dimension Icon, Bruker, USA). AFM was
performed in PeakForce™ QNM™ (Quantitative Nano-
mechanical Property Mapping) mode. Peakforce™
QNM™ is similar to that of classic tapping where the
amplitude oscillation is kept constant, but differs in
that the maximum force applied by the probe was con-
trolled [21].Membrane deformability (elasticity)
Deformability (elasticity) measurements were performed
on the platelets and fibrin networks of the healthy indi-
viduals and patients in the experimental group to deter-
mine whether nano-mechanical property differences
were present. A rapid force-distance curve was recorded
at each pixel. Calibration of the cantilever’s deflection
sensitivity and spring constant allowed the rapid quanti-
tative analysis of these force-distance curves on a num-
ber of different areas on the sample. The curve obtained
was used to calculate Young’s modulus and also to form
adhesion images (between the slope of the curve and the
minimum point of the curve). Deformation is calculated
using the variation between zero and the maximum
force applied. Energy dissipation can be calculated by
determining the area between the approach and the de-
velopment of the retract curve [22–24]. Different silicon
nitride cantilevers (Bruker, USA) and settings were used
for the measurement of each of the specific components
investigated (See Table 2).
Ten cells or areas in the case of fibrin from each pa-
tient were studied. A 500 nm by 500 nm area was
scanned by performing 128 by 128 data points of the in-
dividual force curve measurements. NanoScope Analysis
(Version R3, Bruker, USA) was used to analyze 50 ran-
domly selected force curves to fit to the modulus model
to the unloading portion of the curve. For this study the
Derjaguin-Muller-Toporov Model was used for the de-
termination of Young’s Modulus by fitting the slope of
the obtained force-distance curve to the model [25]. A
curve was only incorporated into the final modulus mea-
surements if the goodness of fit of the data curve to the
modulus model was above 0.85. The goodness of fit is
determined between the model and the acquired data
curve by calculating the ratio of explained variation to
total variation in the data set. Young’s modulus is used
to gauge the rigidity of the membrane that is measured.
The rigidity is representative of the elasticity or deform-
ability of the cell membrane and is usually defined by
the stress divided by the strain on the specific mem-
brane. Higher values indicate decreased deformability,
Table 2 Cantilevers and cantilever parameters (nominal values)
Component investigated Probe name Spring constant (N/m) Resonant frequency Tip radius Peak force (nN)
Fibrin Fibers OTESPA 12–103 345–361 kHz 15 nm 150
Platelet ScanAsyst 0.4 70 kHz 8 nm 4
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blood cells, platelets and fibrin networks.
Thromboelastography®
TEG® was utilized to study the hemostatic profiles of the
participants. Whole blood of the participants was ob-
tained in citrate tubes. The blood was centrifuged at
300 × g for 10 min to obtain PRP. The PRP was stored
in 500 μl aliquots in a −70 °C freezer. On the day of ex-
perimentation, the aliquots were removed from the
freezer and rapidly thawed at room temperature. TEG®
analysis of the individuals was performed on the same
day to prevent variations in machine function from day
to day. Two samples were run simultaneously in the 2
channels of the TEG®. Since it has been found that red
blood cells influence the mechanical properties of clots
due to their viscoelastic properties [26], PRP was used to
assess the functioning of the coagulation cascade in the
presence of platelets. The citrated PRP (340 μl) was
added to the oscillating cup and 20 μl of calcium chlor-
ide (CaCl2) added to activate the coagulation process.
The process was allowed to run until LY30 was reached.
Anticoagulant and antiplatelet medication was not con-
sidered a reason to exclude the patient as these treat-
ments do not affect TEG® analysis, since the action of
thrombin masks any antithrombotic or antiplatelet activ-
ity [27, 28].
Statistical analysis
In SEM to compare fibrin fiber thickness
The measurements of each participant were done using
ImageJ (Version 1,74i, Java) and the values were com-
pared statistically. Statistical analysis was performed on
Statistical Analysis System (SAS) using repeated mea-
sures analysis of variance (ANOVA). A p-value of less
than 0.05 was considered significant.
In AFM to compare platelet- and fibrin fiber-elasticity
The Young’s modulus of 50 randomly selected force-
distance curves with good fit on each cell or area of
every patient, were compared between the 2 groups
(healthy and TIA individuals). SAS software was used to
perform the comparison by utilising the generalized
mixed model for repeated measures function. A p-value
of 0.05 was considered statistically significant. These
comparisons were performed for platelet- and fibrin
fiber-elasticity.In TEG® to compare hemostatic profiles of the 2 groups
The non-parametric Mann–Whitney U test was per-
formed using the SAS software. A two-tailed, one sided
test was performed to determine the p-value. A p-value
of less than 0.05 was considered statistically significant.
Results
Scanning electron microscopy
SEM is a useful tool for studying morphological alter-
ations of platelets that could be indicative of activation
and fibrin fiber arrangement. Red blood cell alterations
may affect the density of the clot and the degree of
platelet activation, for this reason whole blood was not
included in this study.
Figure 1 represents the platelets of healthy- and TIA-
individuals. The healthy platelets are spherical with few
pseudopodia visible (Fig. 1a) indicated by pink arrows.
The presence of numerous pseudopodia, change in
shape and spreading are indicative of activation, but is
not present or expected in the healthy individuals [29].
Since these healthy individuals are not suffering from
any inflammatory condition and no thrombin was added
in vitro, inert or slightly activated platelets were expected.
Slight activation may be due to contact activation during
the preparation of the sample. The healthy platelets are
consistent with previously published results [30].
Figure 1b to h represents the platelets of the TIA pa-
tients in the presence of metabolic syndrome included in
this study. In Fig. 1b and c the typical platelets of the pa-
tients can be seen. These platelets are characterized by
numerous pseudopodia (pink arrows) and spreading
(green arrows) indicating activation. In Fig. 1d, e and f
platelet-platelet interactions, also indicative of platelet
activity, can be seen. Importantly, platelets wees aggregates
are present (as seen in Fig. 1g and h depicted by yellow
arrows) in the TIA individuals. The blue arrows in Fig. 1b,
c, d and e indicate open canalicular systems (OCSs) that
allow granules inside the platelet to exit the platelet.
The fibrin networks of the healthy and TIA individuals
were also studied using SEM. As briefly mentioned the
fibrin networks of healthy individuals typically consist of
thick or major fibers (turquoise arrows) and thin or
minor fibers (purple arrows) [19, 20]. The thick major fi-
bers make up the majority of the clot as shown in Fig. 2a.
In contrast the fibrin networks of TIA individuals have
an altered appearance as shown in Fig. 2b to h when
compared to that of control individuals (Fig. 2a). Fibrin
fibers appear less organized with a higher density of
Fig. 1 Platelets of TIA individuals in the presence of metabolic syndrome. a: Platelet of a typical healthy individual. b-e: TIA platelets. f-h: TIA
platelet interactions and aggregates (Scale bar: 1 μm). Pink arrows: Pseudopodia. Blue arrows: OCS. Green arrows: Platelet spreading. Yellow
arrows: Platelet aggregates
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(orange arrows) covering the clot in some individuals
(Fig. 2e, f and h). Upon closer examination the fibers are
also less taut, folding and twisting (red arrows) forming
an irregular web of fibers as seen in Fig. 2b and c. Fibers
also appear “sticky” creating thick masses of fibrin fibers
(green arrow) as visualized in Fig. 2g.Measurements of fibrin fiber thickness in the 2 groups
were performed and a mean of 98.682 nm and
164.365 nm was determined in the control and experi-
mental groups respectively. A p-value of <0.001 was de-
termined indicating that a statistically significant
increase in fibrin fiber thickness was present in the ex-
perimental group.
Fig. 2 Fibrin networks of a typical healthy individual and TIA individuals. a: Healthy fibrin network (b-h): Fibrin network of TIA in the presence of
metabolic syndrome (Scale bar: 1 μm). Turquoise arrows: Thick major fibers. Purple arrows: Thin minor fibers. Orange arrows: Net-like covering of
thin fibers. Red arrows: Bending, less taut fibers. Green arrow: Sticky mass of fibrin fibers
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Due to the finding on the SEM, AFM was performed on
the PRP of the individuals participating in this study to
determine whether, in conjunction to the morphological
changes, alterations in the nano-mechanical properties
of the platelets and fibrin network fibers, that could
affect coagulation, were present. Figure 3 represents
the images obtained using AFM, indicating that themorphological findings on the AFM correlate with the
findings on the SEM micrographs since platelet- and fi-
brin network-morphology appear similar with both tech-
niques. Figure 3a represents the platelet of a healthy
control individual and Fig. 3b the platelet of a TIA indi-
vidual with activation visible (as seen with the presence
of pseudopodia and spreading). Figure 3c and d (healthy
participants) and 3d (experimental group) represent the
Fig. 3 AFM topography of platelets and fibrin networks. a: Healthy platelet. b: TIA platelet. c: Fibrin network of healthy individual. d: Fibrin
network of individual suffering a TIA
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denser structure in comparison to the healthy group,
similar to that seen using SEM.
Young’s modulus, used to measure the nano-mechanical
properties of the platelets and fibrin fibers were compar-
able to results obtained in previous studies [31]. The
p-values obtained using SAS are represented in Table 3.
Young’s modulus increased significantly (p-value < 0.05) in
both the platelets and fibrin networks of the experimental
group, indicating that the elasticity of these components
decreased in the experimental participants.
Thromboelastography®
The traces obtained from the PRP of the participants
are represented in Fig. 4. Figure 4 represents the trace
from which reaction time (r-time), k-time, alpha angleTable 3 The p-values obtained from generalized mixed model
for repeated measures between the healthy and experimental
groups
Sample Mean Median p-value
Control platelet 48.786 46.3 0.0042*
TIA platelet 54.587 51.1
Control fibrin fiber 12910.84 11505 0.0007*
TIA fibrin fiber 27871.19 22263
* Indicates statistically significant p-values(α-angle), maximum amplitude (MA) and clot lysis after
30 min (LY30) was determined. Figure 4a represents the
traces from healthy control individuals and Fig. 4b rep-
resents the traces obtained form the experimental group.
The traces appear similar in both groups regarding
shape and amplitude. Figure 4c and d represent the
v-curve from which time to maximum rate of thrombus
generation (TMRTG), maximum rate of thrombus gen-
eration (MRTG) and total thrombus generation (TTG)
were determined. Figure 4c represents the v-curve ob-
tained from the healthy participants and Fig. 4d the
v-curves from the experimental group. No differences
could be observed between the participants of the two
groups.
In order to determine whether the viscoelastic proper-
ties of the clots differed between the healthy and the ex-
perimental group, statistical analysis was performed on
each parameter measured. The p-values obtained in the
comparison of the healthy and TIA group are summa-
rized in Table 4. None of the parameters showed statisti-
cally significant differences (p-value less than 0.05)
between the two groups. This indicated that both the
viscoelastic properties of the clot and the coagulation
process were similar in all participants regardless of the
presence of metabolic syndrome. LY30 was determined
for all the individuals, but in all cases it was found to be
0 %, indicating that no clot lysis had taken place 30 min
Fig. 4 TEG® trace and v-curve obtained from healthy and TIA individuals. a: Trace representative of healthy individuals. b: Trace of TIA individuals.
c: v-curve of healthy individual. d: v-curve of a TIA individual
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ticipants, consistent with normal coagulation.
Discussion
Platelets are essential in the prevention of blood loss
and platelet activation is the first sign of coagulation cas-
cade activation [11]. Platelet shape changes consistent
with activation [32] was observed in the experimental
group indicating that the coagulation cascade had been
activated. This activation occurred spontaneously (with-
out the artificial activation of the coagulation cascade by
the addition of thrombin) in the experimental group.
The same activation was not present in the experimental
group indicating that the coagulation cascade had only
been activated in the TIA individuals. These findings
confirm the hypothesis of Wu and Hoak in 1975 as well
as Hirabayashi and his colleagues in 2004 that platelet
activation is closely associated with TIA [33, 34]. Since
chronic inflammation is present in these individuals and
inflammation is closely associated with activation of the
coagulation system, it can be concluded that theactivation of platelets occur prior to the cerebral event.
This indicates that a procoagulant environment is
present in the individuals prior to the onset of the symp-
toms of the TIA and therefore before formation of the
pathological clot. This finding is crucial in the treatment
and prevention of TIA since platelet activation is not a
result of the ischemic event, but rather plays a role in
the development of the attack. Platelet counts were
found to be normal in the diseased individuals indicating
that the number of platelets did not contribute to the at-
tack, but rather that the activation of the platelets was
the crucial step prior to the formation of the clot.
It is well known that platelets increase clot elasticity in
normal physiology since they make up approximately
80 % of a thrombus; consequently any alterations in the
membrane characteristics (such as elasticity) of the
platelets will affect the formed thrombus as well [35]. In
the presence of chronic inflammation (as seen in this
study) the elasticity of the platelets decreased signifi-
cantly, giving rise to more rigid platelets with a de-
creased ability to contract during the final stages of clot
Table 4 The p-values of TEG® parameters obtained with the
Mann–Whitney U test
Parameter Mean Median p-value
Control r-time 510 502.5 0.911
TIA r-time 480 522.5
Control k-value 185 140 0.853
TIA k-value 137 132.5
Control Alpha(α) angle 70.58 69.15 0.436
TIA Alpha(α) angle 69 68.8
Control MA 31.62 30.25 0.190
TIA MA 37.86 35.7
Control G 2.42 2.15 0.165
TIA G 3.32 2.8
Control MRTGG 6.532 5.645 1.000
TIA MRTGG 6.279 6.29
Control TMRTGG 9.749 9.29 0.796
TIA TMRTGG 9.599 10.25
Control TGG 276.999 245.95 0.190
TIA TGG 469.401 313.725
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creased platelet contraction, could consequently result
in less taut fibers and less organized fibrin networks.
Together with platelets, fibrin fibers make up the ma-
jority of the structure of the clot and are the main deter-
minants of the clot mechanics. The fibrin networks of
the diseased participants were therefore studied to deter-
mine whether alterations in fibrin networks could con-
tribute to changes in clot formation that could lead to
the development of a TIA. The fibrin networks of the
TIA individuals appeared greatly altered when compared
to healthy individuals. These findings are consistent with
the findings of other studies that abnormal coagulation
plays a major role in ischemic events [36]. The networks
appeared denser, less organized with sticky thick fibers
that clump together, most likely due to a favouring of
lateral aggregation of the protofibrils, this is also consist-
ent with other studies where it was found that denser fi-
brin networks were associated with a reduction in clot
permeability and consequently clot lysis [36–38]. The
presence of inflammatory cytokines could further de-
crease the permeability of the clot as found by Pera et al.
in 2015 [39, 40]. Although LY30 measured on the TEG®
did not indicate hyperfibrinolysis it cannot comment on
a decrease in clot fibrinolysis which could be present
due to altered fibrin network formation. In some areas
the thin fibers form a net that covers large parts of the
formed clot. The fibrin fibers of the TIA individuals are
significantly thicker than those of the healthy individ-
uals, as seen with statistical analysis. This increase in
thickness is most likely due to the propensity of thefibers to stick together as seen in the experimental
group. The maximum amplitude (MA) of the clot mea-
sured using TEG® corresponds to the speed of fibrin
build-up and fibrin cross-linking during clot formation
and could therefore be used to study whether the altered
fibrin networks affected clot formation. The MA values
of the TIA individuals were similar to that of the healthy
group. It can therefore be concluded that the formation
of the clot was not altered, however the MA does not
comment on the quality or thickness of the fibers that
could contribute to the formation of the pathological
thrombus in the TIA event. Similar to the elasticity of
the platelets, the elasticity of the fibrin fibers also de-
creased (seen with the AFM results) substantiating the
theory that a decrease in platelet elasticity will result in
a decrease in fibrin fiber elasticity, since clots containing
platelets are more elastic than clots without platelets.
Less elastic fibers will make it even more difficult for
clot retraction to take place explaining the slackness of
the fibers seen in the TIA individuals using SEM and
AFM. Although fibrinogen concentration may contribute
to the formation of a pathological clot, this is probably
not the case here, since the rate of clot formation (as
measured by TEG® and several plasma based tests) was
not significantly different from the healthy controls as
would be expected in increased fibrinogen concentrations.
Since chronic inflammation is present in the diseased indi-
viduals and inflammation activates the coagulation cas-
cade, the changes in the fibrin networks can most likely
also be attributed to the continuous inflammatory re-
sponse that activates platelets. This activation of the plate-
lets, since they function very closely with the fibrin
network, is most likely the initiation step of the fibrin net-
work changes seen in the experimental group.
No changes in any of the parameter measured with
TEG® could be detected between the healthy control
group and the diseased experimental group, indicating
that the overall hemostatic profile of the individuals
were not affected by metabolic syndrome leading to TIA
and that the viscoelastic properties of the clots are simi-
lar in the healthy and diseased populations.
Figure 5 and Table 5 represent the findings of this
manuscript and how it relates to the development of TIA.
Conclusion
The findings of this study substantiates the results of
other publications which indicate that fibrin network
morphology is altered in ischemic events such as stroke
[38]. Furthermore it has been postulated that fibrin for-
mation occurs faster in ischemic events in comparison
to normal physiology, producing a denser clot (seen with
SEM) with increased resistance to fibrinolysis, this study
suggests that the quicker fibrin formation and altered
fibrin clot properties is a result of the premature
Fig. 5 Figure summarizing the findings of this manuscript. *Findings represented in Table 5. HDL: High-density lipoprotein; TIA: Transient ischemic
attack; NCEP ATP III: National cholesterol education program – Adult treatment panel III. Since it is hypothesised that metabolic syndrome causes
chronic inflammation that unnecessarily activates the platelets and it is believed that the platelet alterations cause the changes seen in the fibrin
networks, this arrow indicates the major culprit in the development of TIA
van Rooy et al. Cardiovascular Diabetology  (2015) 14:86 Page 11 of 13activation of the coagulation cascade by platelets that
are constantly activated in the presence of chronic in-
flammation as is the case in metabolic syndrome.
This is further shown by the findings of the TEG® indi-
cating that the coagulation cascade is not altered in the
experimental group showing that the cause of the forma-
tion of the clot is due to alterations in the hemostaticTable 5 Summary of the findings of this manuscript according to te
Technique Platelets Fibrin networks
SEM Platelet activation present
seen with presence of
pseudopodia and spreading
Denser, less organized fibrin net
experimental group
Platelet aggregation present
in the experimental group
Thick major fibers sticky and clum
together and thicker than fibers
individuals
Fibers making up clots of the ex
group were less taut with visible
ends not found in the healthy g
AFM Platelets are less elastic in
the diseased individuals
Fibrin fibers are less elastic in the
experimental group
TEG® N/A N/Aprofile of the participants. Platelet- and fibrin fiber-
elasticity is decreased resulting in a less permeable clot.
Although fibrinolysis may be impeded by the alterations
found in the components of coagulation found in this
manuscript, fibrinolysis will still occur, leading to the
transient period of the symptoms that characterize a
TIA.chniques used
Conclusions drawn
works in Platelet activation present, altered fibrin network
formation with the addition of thrombin affecting








A decrease in platelet elasticity affects platelet
contraction and therefore clot retraction, resulting
in altered fibrin network elasticity and network
morphology
TEG® was used to determine whether the alterations
obtained with the results of the other techniques
affected the hemostatic profile of the individuals, but
was found not affect the overall coagulation process
van Rooy et al. Cardiovascular Diabetology  (2015) 14:86 Page 12 of 13The findings of this thesis contributes to research and
the clinical setting by showing that treatment of a TIA
and prevention of future TIA or stroke should focus on
the prevention of platelet activation that could prevent
to the formation of an abnormal fibrin network and a
pathological thrombus.
A limitation to this study is the number of partici-
pants; however, this study is adequately powered.
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